Curing blindness through regenerative cell therapies. We replace what is lost.

StemSight develops off-the-shelf cell therapies to address unmet medical needs in corneal blindness. ​

We are the pioneers of combining iPS-derived cells with functional biomaterials. Our primary goal is to accelerate tissue regeneration, enhance the safety of cell therapies, and simplify cell delivery.

<p><span>The most innovative startup in health and life sciences in Europe at BioFit, 2020</span></p>

The most innovative startup in health and life sciences in Europe at BioFit, 2020

Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Award winner at TechTour’s flagship event, Europe’s Most Innovative Companies, 2022
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023
Finalist at EIT Health Catapult Biotech pitching competition, 2022-2023

About us

The founding team of StemSight is comprised of top scientists in regenerative medicine and tissue engineering for eye applications. The scientific excellence is complemented by our distinguished board of accomplished industry leaders and advisors with extensive global business acumen.
READ MORE

Latest News

2026-03-24 00:00:00

StemSight at the SOT 65th Annual Meeting

StemSight attends the SOT 65th Annual Meeting in San Diego on March 22-25, 2026. Our CSO Tanja Ilmarinen will be presenting at the Ocular Toxicology Specialty Session on March 25, 2026.

 

2026-03-04 00:00:00

StemSight at Sachs European Life Sciences CEO Forum

StemSight attends the 19th Annual European Life Sciences CEO Forum on March 4-5 in Zurich.  Our CEO Laura Koivusalo will take the stage on Day 2 of the event.

 

2026-03-24 00:00:00

StemSight attending BIO Europe and LSX in Lisbon

Our Chief Commercial Officer Ross Macdonald is attending both BIO Europe and LSX in Lisbon on March 23–25, 2026. We invite fellow attendees to engage with us regarding partnership opportunities and to gain further insight into our upcoming Series A.

 

 

2026-02-19 00:00:00

StemSight participates in Japan Entry Acceleration Program (JEAP)

StemSight is selected for competitive Japan Entry Acceleration Program (JEAP) introducing global high-potential biomedical startups to Japan. Read the full press release here.


More News

Want to know more?

Interested to join our next investment round? Want to hear about our latest developments? Just thought of someone we absolutely need to meet?

Send us a message!

CONTACT US

Subscribe to our newsletter

Subscribe now

Supported by:

Co-funded by: